These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 26816833)

  • 1. The current and future role of magnetic resonance imaging in prostate cancer detection and management.
    Radtke JP; Teber D; Hohenfellner M; Hadaschik BA
    Transl Androl Urol; 2015 Jun; 4(3):326-41. PubMed ID: 26816833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
    Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
    Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.
    Radtke JP; Kuru TH; Bonekamp D; Freitag MT; Wolf MB; Alt CD; Hatiboglu G; Boxler S; Pahernik S; Roth W; Roethke MC; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):283-91. PubMed ID: 27184812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.
    Radtke JP; Boxler S; Kuru TH; Wolf MB; Alt CD; Popeneciu IV; Steinemann S; Huettenbrink C; Bergstraesser-Gasch C; Klein T; Kesch C; Roethke M; Becker N; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):288-96. PubMed ID: 26078202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
    Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
    Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study.
    Washino S; Kobayashi S; Okochi T; Kameda T; Konoshi T; Miyagawa T; Takayama T; Morita T
    BMC Urol; 2018 May; 18(1):51. PubMed ID: 29843694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
    Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
    Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
    Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
    Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
    Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
    Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
    BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.
    Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L
    Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study.
    Mariotti GC; Falsarella PM; Garcia RG; Queiroz MRG; Lemos GC; Baroni RH
    Eur Radiol; 2018 Jan; 28(1):11-16. PubMed ID: 28687911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
    Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
    Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.